Category
15 articles
Generic availability has made azithromycin one of the cheapest antibiotics on US pharmacy shelves, but affordability cuts both ways. This analysis examines how rock-bottom pricing influences prescribing behavior in cash-pay and telehealth settings, and what stewardship-minded clinicians can do about it.
Direct-to-consumer telehealth has made azithromycin one of the most frictionless prescriptions in American healthcare. This opinion analysis weighs that convenience against missed cardiac screening, undetected interactions, and viral misdiagnosis — and proposes concrete guardrails for virtual care.
Mounting resistance to beta-lactams and fluoroquinolones has prompted a measured reexamination of azithromycin's place in modern therapeutics. This article reviews where current evidence supports its reintegration into frontline protocols, where overuse persists, and how clinicians can navigate prescribing decisions responsibly in a landscape defined by diminishing options.
Azithromycin is appearing with increasing frequency on dental prescription pads across the United States, yet clear clinical consensus on its appropriate role in oral surgery remains elusive. This article examines the microbiological evidence, the stewardship implications, and the practical decision points that should guide oral surgeons and dentists before reaching for a macrolide. Without a structured prescribing framework, the dental setting risks becoming a significant contributor to communi
Azithromycin is quietly gaining traction among ENT specialists and primary care clinicians as an off-label option for chronic rhinosinusitis, driven largely by its immunomodulatory properties rather than its antimicrobial activity. Yet this indication rarely surfaces in formal stewardship discussions, leaving prescribers without a clear evidence-based framework. This article examines the mechanistic rationale, the quality of available data, and practical guidance for determining when — and wheth
Evidence-based guidelines have long positioned azithromycin as a first-line option for community-acquired respiratory infections, yet mounting regional resistance surveillance data is prompting serious questions about whether monotherapy remains adequate across all US patient populations. This article examines the clinical tension between national guideline recommendations and local epidemiological realities, offering a structured framework for respiratory clinicians navigating this increasingly
Azithromycin occupies a genuinely irreplaceable position in the management of nontuberculous mycobacterial infections and MAC prophylaxis—contexts that bear little resemblance to the reflexive Z-pack prescriptions driving resistance concerns. Understanding when this macrolide constitutes cornerstone therapy, rather than a convenient empiric choice, is essential for clinicians navigating complex immunocompromised and pulmonary patient populations.
The order and timing of antibiotic administration is rarely treated as a clinical variable—but mounting evidence suggests it should be. When azithromycin and fluoroquinolones are prescribed sequentially or concurrently, the consequences for treatment failure rates and resistance selection differ meaningfully depending on how the regimen is structured. This article offers clinicians a framework for making those decisions with greater precision.
During the COVID-19 pandemic, azithromycin became one of the most prescribed and most debated medications in modern medical history — not primarily because of scientific consensus, but because of political pressure, media amplification, and institutional urgency. This article examines what the clinical trials actually demonstrated, how prescribing patterns were distorted by non-clinical forces, and what clinicians should carry forward from one of the most instructive episodes in recent pharmacol
Azithromycin is frequently selected empirically for respiratory infections attributed to atypical organisms, yet the diagnostic certainty underpinning many of these prescribing decisions is far weaker than clinicians may appreciate. This article examines the genuine evidence base for azithromycin's activity against Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila, while interrogating how diagnostic ambiguity and clinical pattern-matching may be fueling unnecessary macr
Beyond its antimicrobial applications, azithromycin has attracted growing interest in gastroenterology as a macrolide prokinetic agent for conditions including gastroparesis, postoperative ileus, and functional dyspepsia. The pharmacological rationale is compelling, but the clinical evidence is considerably more complicated. This article critically evaluates the efficacy data, addresses the underappreciated problem of tachyphylaxis, and provides clinicians with a structured framework for determi
Azithromycin's broad-spectrum activity extends well beyond its intended pathogen targets, disrupting the delicate balance of commensal gut bacteria in ways that can persist for weeks to months after a course ends. Clinicians making prescribing decisions must now weigh not only immediate therapeutic benefit but also the downstream consequences of post-treatment dysbiosis. This article synthesizes current evidence on microbiome disruption, secondary infection risk, and recovery trajectories to sup
Rising resistance rates and evolving patient profiles are forcing prescribers to look beyond azithromycin for common respiratory and sexually transmitted infections. This clinical guide offers structured decision-making pathways and evidence-based substitution strategies tailored to US prescribing contexts. Understanding when—and how—to pivot away from azithromycin is now a core competency in responsible antibiotic stewardship.
As macrolide resistance continues to reshape the treatment landscape for community-acquired pneumonia, clinicians across the United States are revisiting azithromycin-based combination regimens with fresh scrutiny. Emerging clinical data from hospital systems in multiple US regions suggest that strategic pairing of azithromycin with beta-lactams may still offer meaningful advantages for select patient populations. This article examines the evidence, the pathogens, and the practical decision poin
Every unnecessary azithromycin prescription is a small vote for a future where the antibiotic no longer works. Across the United States, azithromycin continues to be prescribed at high rates for respiratory illnesses that are viral in origin, feeding resistance patterns that undermine treatment outcomes for patients who genuinely need the drug. This investigation examines the scope of the problem, the real-world consequences for patients and communities, and what meaningful change actually requi